Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias
Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias
复制标题
DOI：
10.1111/j.1468-1331.2009.02617.x
复制
发表时间：
2009-08-01
影响因子：
5.1
通讯作者：
Trenkwalder, C.
中科院分区：
文献类型：
--
作者：
Bachmann, C. G.;Zapf, A.;Trenkwalder, C.
背景和目的：几项研究表明，与年龄匹配的健康受试者相比，晚期帕金森病（PD）患者的体重过低。我们的目的是调查运动障碍PD患者是否表现出体重改变，并观察药物与其他推定的决定因素之间的相关性。方法：对德国一家运动障碍诊所6个月内收治的166例伴有波动和运动障碍的PD患者的体重指数（BMI）、发病年龄、病程、统一帕金森病评定量表运动评分、饮食协调和用药情况进行调查。结果：分析显示，4.2%的PD患者体重过轻（BMI < 18.5 kg/m(2)）， 46.4%的PD患者正常（BMI > 18.5 ~ 25 kg/m(2)）， 33.7%的PD患者超重（BMI > 25 ~ 30 kg/m(2)）， 15.7%的PD患者肥胖（BMI > 30 kg/m(2)）。每日左旋多巴剂量/ kg和总多巴胺能剂量/ kg体重与BMI呈负相关。总体而言，患者的BMI在2年随访期间无明显变化。结论：总而言之，与来自德国联邦统计局调查的年龄匹配组的对照人群相比，晚期PD患者的BMI降低。我们的研究结果表明，BMI较低的患者接受较高的累积左旋多巴剂量，左旋多巴可能是PD患者体重减轻的原因。
Background and purpose:Several studies suggested that patients with advanced Parkinson's disease (PD) showed a too low body weight when compared with age-matched, healthy subjects. We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants.Methods:Charts of 166 PD patients with fluctuations and dyskinesias, admitted within 6 months to a German movement disorders clinic, were investigated for body mass index (BMI), age at onset, disease duration, Unified Parkinson's Disease Rating Scale motor score, eating coordination and medication.Results:Analysis showed that 4.2% of PD patients were underweight (BMI < 18.5 kg/m(2)), 46.4% were normal (BMI > 18.5-25 kg/m(2)), 33.7% were overweight (BMI > 25-30 kg/m(2)), 15.7% were obese (BMI > 30 kg/m(2)). Daily levodopa dosage per kg and total dopaminergic dosage per kg body weight were negatively correlated with BMI. Overall, patients' BMI had not significantly changed within 2 years of follow-up.Conclusions:In sum, advanced PD patients showed a reduced BMI when compared with a control population obtained from an age-matched group taken from a survey of the German Federal Office for Statistics. Our findings indicate that patients with a lower BMI received a higher cumulative levodopa dosage and that levodopa may be responsible for weight loss in PD.